GLPG Galapagos

    Mechelen, Belgium; 3 January 2007 - Galapagos NV (Euronext & LSE:
GLPG) announced that its service division BioFocus DPI has expanded
and extended its longstanding drug discovery collaboration with Amgen
through 2007 and 2008.  BioFocus DPI will continue to provide
biology, computational and medicinal chemistry services and will
supply biologically-directed library compounds to Amgen's discovery
programs.  Under the terms of the extended agreement, Galapagos will
receive an upfront fee of $2.4 million as a payment for 2007 research
costs.  Additionally, Galapagos may receive compensation in the form
of library and technology access fees, research fees, milestone
payments, and bonuses.

The initial collaboration,  announced in January  2003, involves  the
identification  of  lead  candidates  against  multiple  ion  channel
targets.  The agreement announced today expands this collaboration to
include all  classes  of targets,  including  ion channel,  GPCR  and
kinase targets.   Additionally, the  agreement has  been expanded  to
include the supply of  BioFocus DPI's compound collection  comprising
700,000 synthetic small molecules and its proprietary natural product
compound collection  containing  145,000  pre-purified  subfractions,
pure natural products, and semi-synthetic natural products.

"The additional breadth and depth gained by BioFocus DPI's drug
discovery offering this year have helped us to expand our strong
collaborative relationship with Amgen," said Onno van de Stolpe,
Chief Executive Officer of Galapagos. "We are excited that the
potential hits arising from BioFocus DPI's unique library collections
could provide promising lead candidates for Amgen's discovery
programs over the next two years."

About Galapagos

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone  and joint  diseases, cachexia,  and menopausal  hot
flashes.    Its  division  BioFocus  DPI  offers  a  full  suite   of
target-to-drug discovery products and services to pharmaceutical  and
biotech companies,  encompassing  target  discovery  and  validation,
screening and  drug discovery  through  to delivery  of  pre-clinical
candidates.  BioFocus DPI also provides adenoviral reagents for rapid
identification  and  validation  of  novel  drug  targets,   compound
libraries for drug  screening as  well as  chemogenomics and  ADME[1]
database  products  to  select  targets  and  compounds.    Galapagos
currently  employs  450  people  and  operates  facilities  in  eight
countries, with  global  headquarters  in Mechelen,  Belgium.    More
information  about  Galapagos  and  BioFocus  DPI  can  be  found  at
www.glpg.com.

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

[1] ADME is the acronym for Absorption, Distribution, Metabolism, and
Excretion: Meeting parameters against these four criteria is critical
to the success of a pharmaceutical compound as a drug.

- ---END OF MESSAGE---






Copyright � Hugin ASA 2007. All rights reserved.

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Galapagos (LSE:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024